| Author | Post |
|---|
Bane
Research Team
| Joined: | Sat Jan 26th, 2008 |
| Location: | Norway |
| Posts: | 973 |
| Status: |
Offline
|
|
Posted: Tue Dec 8th, 2015 22:41 |
|
Angiotensin receptor blockers use and the risk of lung cancer: A meta-analysis
http://jra.sagepub.com/content/early/2015/10/03/1470320315607391.long
"This meta-analysis indicated that ARBs may be associated with decreased risk of LC"
|
Bane
Research Team
| Joined: | Sat Jan 26th, 2008 |
| Location: | Norway |
| Posts: | 973 |
| Status: |
Offline
|
|
Posted: Sun Dec 27th, 2015 20:56 |
|
Potential coeliac disease markers and autoimmunity in olmesartan induced enteropathy: A population-based study
http://www.dldjournalonline.com/article/S1590-8658(15)30042-6/abstract
"Incidence of severe olmesartan-associated enteropathy was low. Autoimmune phenomena were present in a subset of cases and reversed after olmesartan removal"
|
Prof Trevor Marshall
Foundation Staff
|
Posted: Sun Dec 27th, 2015 23:02 |
|
Today's researchers are absolutely clueless, and unable to even Google for ideas...
http://lmgtfy.com/?q=autoimmune+olmesartan
..Trevor..
|
Sallie Q
Support Team
|
Posted: Mon Dec 28th, 2015 03:48 |
|
not knowing who this is
Olmesartan and Recovery from Autoimmune Disease ... but I really like the sunnies 
____________________
VideoMPsep'08(ptBrk'11 OLM=3x20mg)Dx Depressn'70,node,brCancer'90,BCC ?Bowen05,Sjogren08|SxCFS,RA,stroke,ASD,reflux 25D=9ng/ml_Nov'17AvoidImmuneSuppression
|
Bane
Research Team
| Joined: | Sat Jan 26th, 2008 |
| Location: | Norway |
| Posts: | 973 |
| Status: |
Offline
|
|
Posted: Fri Jul 8th, 2016 01:48 |
|
The effect of angiotensin system inhibitors (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) on cancer recurrence and survival: a meta-analysis.
http://www.ncbi.nlm.nih.gov/pubmed/27158979
"This meta-analysis provides evidence that the use of ACEIs or ARBs in cancer patients can lead to a 40 and 25% reduction in the risk of cancer recurrence and mortality"
|
scooker48
Member*
|
Posted: Fri Jul 8th, 2016 02:04 |
|
Good news .
Sherry
____________________
D25, Total: 12 measured 11/3/15 Started MP=01/04/05 Diagnosis: Sarc 12/04; "cat scratch disease" or necrotizing graunulomas 10/88; Raynaud's (diagnosed 1980?)
|
Bane
Research Team
| Joined: | Sat Jan 26th, 2008 |
| Location: | Norway |
| Posts: | 973 |
| Status: |
Offline
|
|
Posted: Fri Jul 8th, 2016 02:08 |
|
scooker48 wrote:
Good news.
Sherry
yes
Is angiotensin-converting enzyme inhibitors/angiotensin receptor blockers therapy protective against prostate cancer?
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872747/
Overall, this study indicates that use of RAS inhibitors may be associated with a decreased risk of prostate cancer. Large-scale well designed studies are needed to further explore this association.
Angiotensin receptor blockers (ARBs) reduce the risk of lung cancer: a systematic review and meta-analysis
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612864/
In conclusion, our meta-analysis demonstrated that ARBs was significantly associated with lower lung cancer.
|
Nyima
Support Team
| Joined: | Wed Apr 27th, 2011 |
| Location: | United Kingdom |
| Posts: | 2601 |
| Status: |
Offline
|
|
Posted: Fri Jul 8th, 2016 16:24 |
|
Great find. And I'm assuming these benefits were noted at 'normal' doses, so researchers are only viewing the very fringe of what is possible with ARBs.
____________________
MP start Dec 10 (2 mo. break Jan-Mar '11) | Multinodular thyroid | frequent illness| fatigue | brain-fog | gluten intolerance (poss coeliac), eczema with dairy products | 25D (ng/ml): 4(14 Apr 11), 5.3(26 Apr 13), 4(Jan 14), 5.5(July 14)
|
Bane
Research Team
| Joined: | Sat Jan 26th, 2008 |
| Location: | Norway |
| Posts: | 973 |
| Status: |
Offline
|
|
Posted: Thu Dec 1st, 2016 04:24 |
|
Mortality benefit of long-term angiotensin-converting enzyme inhibitors or angiotensin receptor blockers after successful percutaneous coronary intervention in non-ST elevation acute myocardial infarction.
https://www.ncbi.nlm.nih.gov/pubmed/27865680
CONCLUSIONS:
In this observational study of patients with NSTEMI, all of them treated successfully by PCI, the use of ACEIs/ARBs was significantly associated with a lower risk of four-year all-cause mortality.
|
Current time is 18:12 | Page:   ... 9 10 11 12 13 14 |
|
